DiaMedica Therapeutics Inc. (DMAC)

2.5900 +0.0100 (+0.39%) At close: 04:00PM EDT

DiaMedica Therapeutics Inc.

301 Carlson Parkway
Suite 210
Minneapolis, MN 55305
United States
(763) 496-5454
https://www.diamedica.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 18

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Dietrich John Pauls MBA	President, CEO & Director	818.61k	N/A	1971
Mr. Scott Kellen CPA	CFO & Corporate Secretary	485.43k	N/A	1965
Dr. Kirsten L. Gruis M.D., M.S.	Independent Consultant	449.29k	N/A	1973
Dr. Ambarish Shah Ph.D.	Chief Technology Officer	N/A	N/A	N/A
Mr. Dominic R. Cundari	Chief Commercial Officer	N/A	N/A	1951
Mr. David J. Wambeke	Chief Business Officer	N/A	N/A	1984
Dr. Lorianne K. Masuoka M.D.	Chief Medical Officer	N/A	N/A	1961

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Corporate governance

DiaMedica Therapeutics Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.